OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes

OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes
Ocugen cash extends to 2028

Ocugen, Inc. announced a first quarter 2026 update, revealing that the company anticipates its cash position will support operations into 2028.

The update includes positive data from its OCU410 program and the completion of enrollment for both OCU400 and OCU410ST clinical trials. The company also noted continued advancements toward submitting Biologics License Applications (BLA) for its gene therapy candidates. This positions Ocugen, Inc. to potentially accelerate its strategy in the competitive gene therapy sector.

Ocugen previously reported a 31 percent reduction in GA lesion growth with a medium dose of OCU410 in a Phase 2 trial. The company also asserted that OCU410 demonstrated nearly double the treatment effect compared to approved therapies in the same trial phase, along with safety and treatment effect advantages in earlier program updates. These findings support ongoing trial development and regulatory milestones.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.